Equity Bancshares: Cencora Acquires OneOncology, Enhancing Independent Oncology Practices

Cencora's Strategic Acquisition: A New Era for Independent Oncology Practices

Cencora, Inc.'s recent announcement of its acquisition of TPG's equity interest in OneOncology marks a significant milestone for the independent oncology community. OneOncology, a physician-led platform dedicated to enhancing the capabilities of independent oncology practices, has seen substantial growth thanks to significant investments and support from TPG. Dr. Jeff Patton, CEO of OneOncology, expressed optimism about the partnership with Cencora, underlining the shared commitment to fostering independence among healthcare providers while improving access to high-quality cancer care. This acquisition not only solidifies OneOncology's operational framework but also positions it to further amplify its impact in the oncology space.

Cencora's investment is expected to empower OneOncology with enhanced clinical innovation, technology advancements, and growth strategies tailored specifically for independent practices. Bob Mauch, President & CEO of Cencora, emphasized that this acquisition aligns with their overarching strategy of supporting pharmaceutical-centric, growth-oriented investments. By collaborating with OneOncology, Cencora aims to leverage its extensive experience in specialty care to facilitate operational efficiencies and improve the overall value delivered to physicians and patients. The synergy between Cencora and OneOncology is poised to provide significant benefits, particularly as the healthcare landscape continues to evolve and independent practices seek sustainable growth.

As Cencora and OneOncology move forward, their partnership is set to play a pivotal role in addressing the complexities associated with cancer care delivery. The agreement signals a commitment to not just maintaining independence but also enhancing the quality of care through innovative solutions. This collaborative effort is likely to resonate across the oncology community, as it highlights the importance of supporting independent practices in delivering specialized care tailored to the needs of patients nationwide. The expected acceleration in OneOncology's capabilities, fueled by Cencora's resources and expertise, reinforces the potential for improved patient outcomes and greater access to essential oncology services.

In addition to this acquisition, the healthcare technology sector continues to experience significant shifts. Curitics Health Solutions has appointed John Gorman as Executive Advisor, bringing extensive experience in Medicare Advantage and health equity. Gorman's expertise is expected to enhance Curitics' strategic approach to market expansion and product offerings, particularly in AI-driven clinical intelligence and value-based care.

Meanwhile, Fanbase, a creator-first social platform, is concluding its equity crowdfunding round, aiming to empower creators by allowing them to have ownership in the platform. With significant advancements made throughout 2025, Fanbase seeks to enhance its scalability and long-term success, reflecting a growing movement towards creator ownership in digital spaces.